Article
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Blood cancer journal - 11 Jan 2022
Fiskus Warren, Boettcher Steffen, Daver Naval, Mill Christopher P, Sasaki Koji, Birdwell Christine E, Davis John A, Takahashi Koichi, Kadia Tapan M, DiNardo Courtney D, Jin Qi, Qi Yuan, Su Xiaoping, McGeehan Gerard M, Khoury Joseph D, Ebert Benjamin L, Bhalla Kapil N
Abstract excerpt
Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressing mutant (mt)-NPM1. Following MI treatment, although clinical responses are common, the majority of patients with AML with MLL1-r or mt-NPM1 succumb to their disease....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.